Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis

In a development that's set to change the lives of many patients, Blueprint Medicines’ Ayvakit has finally won its long-awaited FDA approval to treat indolent systemic mastocytosis (SM).